Results 191 to 200 of about 21,646 (232)

Dabigatran: A Primer for Neurosurgeons

World Neurosurgery, 2013
This study sought to present an overview of dabigatran, a new anticoagulant, and to discuss the implications for the perioperative management of patients taking dabigatran.We reviewed the English literature pertaining to the new oral anticoagulant, dabigatran (Pradaxa).Dabigatran has the advantage of providing rapid and steady anticoagulation without ...
Jennifer E, Fugate, Alejandro A, Rabinstein, Robert D, McBane, Giuseppe, Lanzino   +3 more
openaire   +2 more sources

The Antithrombotic Effect of Dabigatran

Canadian Journal of Cardiology, 2014
A 72-year-old man presented to the emergency department because of a sudden onset of left-sidedweakness. The patient had his first cerebral vascular accident at the age of 49 years. Atrial fibrillation (AF) and hypertension were diagnosed at that time.
Chao-Lin, Lee, Hsueh-Han, Wang, Hsuan-Ming, Tsao   +2 more
openaire   +2 more sources

Reversal of Dabigatran with Idarucizumab

Expert Review of Cardiovascular Therapy, 2016
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R, Sodha, Frank W, Sellke
openaire   +2 more sources

Idarucizumab for Dabigatran Reversal

New England Journal of Medicine, 2015
Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of ...
Pollack Jr, C.V., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., Dubiel, R., Huisman, M.V., Hylek, E.M., Kamphuisen, P.W., Kreuzer, J., Levy, J.H., Sellke, F.W., Stangier, J., Steiner, T., Wang, B., Kam, C.W., Weitz, J.I.   +17 more
openaire   +3 more sources

Dabigatran, bleeding, and the regulators

BMJ, 2014
Thomas J Moore and colleagues highlight the differences in how US and European regulators managed the safety problems of the new anticoagulant dabigatran and ask both to think again and mandate plasma monitoring of ...
Thomas J, Moore, Michael R, Cohen, Donald R, Mattison   +2 more
openaire   +2 more sources

Dabigatran in Clinical Practice

Clinical Therapeutics, 2012
Stroke and systemic thromboembolism remain critical causes of mortality and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. Randomized clinical data demonstrate dabigatran to be
Rangadham, Nagarakanti, Christopher R, Ellis   +1 more
openaire   +2 more sources

Pros and cons of dabigatran

American Journal of Health-System Pharmacy, 2011
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Christine M, Cheng, Megan R, McCurdy, Heather A, Wong, Steven R, Kayser   +3 more
openaire   +2 more sources

Dabigatran-Induced Esophagitis

Clinical Gastroenterology and Hepatology, 2014
We report 2 cases of drug-induced esophagitis associated with dabigatran, a new oral anticoagulant. Both patients were prescribed dabigatran at 110 mg twice daily for atrial fibrillation as an alternative to warfarin. The first case was a 70-year-old man who had been taking dabigatran for 14 days and was referred to our hospital because of retrosternal
Akifumi, Ootani, Yoshihiro, Hayashi, Yugo, Miyagi   +2 more
openaire   +2 more sources

A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects

Drug Research, 2019
Abstract Purpose Due to bioanalytical limitations it was previously not possible to evaluate the pharmacokinetics of dabigatran etexilate. We have developed validated methods to assay dabigatran etexilate, unconjugated dabigatran, and total dabigatran that will allow for a complete investigation into the pharmacokinetics of dabigatran etexilate ...
Mohammed, Bouhajib, Zia, Tayab
openaire   +2 more sources

Dabigatran/Dabigatran etexilate

Drugs of the Future, 2005
null Sorbera, L.A., null Bozzo, J., null Castaner, J.   +2 more
openaire   +1 more source